About


We are developing treatments that impact the progress of major ophthalmic diseases. A clinically-validated pharmaceutical treatment for cataract is our first priority. 

Read More »

Business


To commercialise new chemicals that slow or arrest the progress of ophthalmic diseases caused by Calpain and other validated targets.

Read More »

Technology


Novel chemical compounds that impact the molecular level cause, and not the symptom, of the ophthalmic disease.

Read More »

Pipeline


Our focus is on diseases that are associated with front and back of the eye where there is currently no interventional standard or orphan drug therapy. See where our efforts are concentrated...

Read More »

People


Our enthusiastic team is made up of professional business experts and private investors, along with science, regulatory and expert ophthalmology surgeon advisors.

Read More »

News


View the latest updates and news from Calpain Therapeutics…

Read More »